Login to Your Account

MannKind Shares Sink on 2nd Afrezza Complete Response

By Marie Powers

Friday, January 21, 2011
MannKind Corp. took one squarely on the chin Thursday as the market responded to breaking news late Wednesday that the FDA had issued a second complete response letter for inhaled insulin candidate Afrezza (insulin human [rDNA origin] to treat adults with Type I and Type II diabetes. (See BioWorld Today, Jan. 20, 2011.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription